CYP2D6 基因 rs1080985 单核苷酸多态性对阿尔茨海默病患者使用多奈哌齐治疗反应的影响。
Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease.
机构信息
Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, Poland.
出版信息
Neuropsychiatr Dis Treat. 2013;9:1029-33. doi: 10.2147/NDT.S46689. Epub 2013 Jul 29.
BACKGROUND
Recent data indicate that the rs1080985 single nucleotide polymorphism of the cytochrome P450 (CYP) 2D6 gene may affect the response to treatment with donepezil in patients with Alzheimer's disease. There is also evidence that the common apolipoprotein E (APOE) polymorphism may affect the response to treatment with donepezil in Alzheimer's disease. We investigated the association between response to donepezil and the rs1080985 single nucleotide polymorphism, the minor allele (G) of which was previously reported to be associated with a poor response to this drug in patients with Alzheimer's disease. The common APOE polymorphism was also assessed for its relevance to the outcome of this treatment.
METHODS
Analysis of CYP2D6 and APOE polymorphisms was undertaken in 88 naive Caucasian patients with Alzheimer's disease. All patients received treatment with donepezil for at least 10 months, and the response to treatment was then assessed according to the National Institute for Health and Clinical Excellence criteria.
RESULTS
No significant differences were observed in distribution of the CYP2D6 rs1080985 single nucleotide polymorphism or common APOE polymorphism between responders (68.2%) and nonresponders (31.8%) to treatment with donepezil.
CONCLUSION
Our results suggest that neither the CYP2D6 nor the APOE polymorphism influences the response to treatment with donepezil in a Polish population with Alzheimer's disease.
背景
最近的数据表明，细胞色素 P450（CYP）2D6 基因的 rs1080985 单核苷酸多态性可能影响阿尔茨海默病患者使用多奈哌齐治疗的反应。也有证据表明，常见的载脂蛋白 E（APOE）多态性可能影响阿尔茨海默病患者使用多奈哌齐治疗的反应。我们研究了多奈哌齐治疗反应与 rs1080985 单核苷酸多态性之间的关系，该多态性的次要等位基因（G）先前被报道与阿尔茨海默病患者对该药物的反应不良有关。还评估了常见的 APOE 多态性与这种治疗结果的相关性。
方法
在 88 名未接受过治疗的高加索裔阿尔茨海默病患者中进行了 CYP2D6 和 APOE 多态性分析。所有患者均接受多奈哌齐治疗至少 10 个月，然后根据国家卫生与临床卓越研究所（NICE）的标准评估治疗反应。
结果
在对多奈哌齐治疗有反应的患者（68.2%）和无反应的患者（31.8%）之间，CYP2D6 rs1080985 单核苷酸多态性或常见 APOE 多态性的分布无显著差异。
结论
我们的结果表明，在波兰的阿尔茨海默病患者中，CYP2D6 或 APOE 多态性均不影响多奈哌齐治疗的反应。
Zotero 插件